Co-expression of renin-angiotensin system genes in human adipose tissue

Engeli, Stefan; Gorzelniak, Kerstin; Kreutz, Reinhold; Runkel, N.; Distler, A.; Sharma, Arya M.

doi:10.1097/00004872-199917040-00014

Cited by 215 publications

(153 citation statements)

References 34 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…In addition, components of RAS could also be produced in some tissues (local RAS or tissue RAS), such as adipose tissue, brain, heart and so on. [11][12][13][14] Furthermore, Ang II can also be generated by enzymes of the nonrenin-angiotensin system, such as cathepsin D and cathepsin G. [15][16][17][18] So far, it is generally believed that Ang II is derived from AGT, irrespective of which way is chosen for its formation.…”

Section: Introductionmentioning

confidence: 99%

Knockdown of angiotensinogen by shRNA-mediated RNA interference inhibits human visceral preadipocytes differentiation

Jiang

2009

Int J Obes

View full text Add to dashboard Cite

Objective: The immediate cause of obesity is the massive deposition of subcutaneous and visceral fat attributing to the continuous proliferation and differentiation of preadipocytes. The identification of the underlying molecular mechanisms of preadipocytes differentiation is urgent, and will have an important role in plastic and reconstructive surgical procedures. Methods: Two small hairpin RNA (shRNA)-mediated RNA interference plasmids have been constructed on the basis of the activity of H1 promoter-driven expression vector psiRNA-hH1neo to suppress the expression of angiotensinogen (AGT) in human preadipocytes-visceral (HPA-v). Subsequently, glycerol-3-phosphate dehydrogenase (G3PDH) activity and intracytoplasmic lipids content were detected during the process of HPA-v differentiation. Results: Small hairpin RNA-expressing vectors have been successfully constructed to suppress the expression of AGT significantly. Both intracytoplasmic lipids content and G3PDH activity decreased to a certain extent compared with that in the control group in the whole process of HPA-v differentiation. Conclusions: Two shRNA-mediated AGT-targeting plasmids inhibited the process of HPA-v differentiation to a certain extent. However, the accumulation of intracytoplasmic lipids was not exclusively determined by the expression of AGT, and it may also be regulated by other factors. In conclusion, this study provided a method to inhibit the process of preadipocytes differentiation, and it may have a role in obesity treatment and adipose tissue engineering application.

show abstract

Section: Introductionmentioning

confidence: 99%

Knockdown of angiotensinogen by shRNA-mediated RNA interference inhibits human visceral preadipocytes differentiation

Jiang

2009

Int J Obes

View full text Add to dashboard Cite

show abstract

“…31 In vitro, it has been demonstrated that angiotensin II stimulates the prostacylin in the adipocytes, which stimulates the differentiation of the precursors of adipocytes. 17,18 In addition, the adipose tissue contains the main components of RAS: angiotensin, ACE, angiotensin I and angiotensin II receptors 15,16 with differential expression if the subcutaneous or omental fat is studied.…”

Section: Discussionmentioning

confidence: 99%

“…Accordingly, the presence of angiotensinogen, of the ACE and the type 1 and 2 receptors for angiotensin II has been shown in human adipose tissue. 15,16 Angiotensin II could have an important role in the growth and differentiation of this tissue. 17 It has been demonstrated in vitro that angiotensin II stimulates the synthesis of prostacyclin in the adipocytes, which stimulates the differentiation of the precursors of adipocytes.…”

Section: Introductionmentioning

confidence: 99%

The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease

Riera-Fortuny

Real

Chaves³

et al. 2004

Int J Obes

View full text Add to dashboard Cite

OBJECTIVE:To analyse the relation between overweight, obesity and fat distribution with I/D polymorphism of the angiotensinconverting enzyme (ACE) gene and its association with coronary heart disease (CHD). DESIGN: Cross-sectional, case-control study. SUBJECTS: A total of 185 cases (141 males) who had suffered at least one episode of CHD and 182 controls (127 males). MEASUREMENTS: Body mass index, waist circumference, blood pressure, plasma total cholesterol, triglycerides, HDL cholestrol and fasting glucose were measured with standard methods, genotyping the I/D polymorphism of ACE gene. RESULTS: Obesity and abdominal fat deposit are associated with CHD in women, but not independently. We have found an association between obesity and abdominal fat deposit with the ACE gene I/D polymorphism in subjects with CHD. Subjects with CHD and DD or ID genotypes have significantly higher prevalence of obesity and abdominal fat deposit and higher values of weight and waist circumference. In addition, the DD and ID genotypes increased crude OR of obesity. The DD and ID genotypes of the ACE gene I/D polymorphism and BMI are independently associated with CHD. CONCLUSION: There is a relation between the type and grade of obesity with the genotypes of the ACE gene I/D polymorphism in subjects with CHD.

show abstract

“…[4][5][6] Human adipocytes express mRNA and protein of many components of the RAAS, including angiotensinogen, angiotensinconverting enzyme and angiotensin receptors. 7 The local generation and release of angiotensin II (Ang II) by adipose tissue may therefore contribute to hypertension and can also influence adipocytokine secretion, thereby having a potential role in the development of features of the metabolic syndrome. 5 Guidelines from the European Society of Hypertension recommend that RAAS inhibition with angiotensin-converting enzyme inhibitors should be preferred over calcium channel blockers, b-blockers and thiazide diuretics for anti-hypertensive therapy in patients with metabolic syndrome.…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

Krone

Hanefeld

Hf³

et al. 2010

J Hum Hypertens

View full text Add to dashboard Cite

Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension. Chronic renin-angiotensin-aldosterone system (RAAS) activation, shown by elevated plasma renin activity (PRA), is implicated in many of the features of metabolic syndrome. The direct renin inhibitor aliskiren may be of benefit in this patient group as aliskiren targets the RAAS at the rate-limiting step. In this double-blind study, 141 patients with hypertension (mean baseline BP 155/93 mm Hg) and metabolic syndrome (modified National Cholesterol Education Program ATP III criteria) were randomized to aliskiren 300 mg or irbesartan 300 mg once daily. Patients treated with aliskiren 300 mg had their mean sitting blood pressure (BP) lowered by 13.8/ 7.1 mm Hg after 12 weeks, significantly greater (Pp0.001) than the 5.8/2.8 mm Hg reduction observed in patients treated with irbesartan 300 mg. A significantly greater proportion of patients treated with aliskiren achieved BP control to o135/85 mm Hg (29.2 vs 16.7% with irbesartan; P ¼ 0.019). Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both Po0.001). Aliskiren and irbesartan had similar effects on glucose and lipid profiles and on a panel of biomarkers of inflammation and cardiovascular risk. Both aliskiren and irbesartan were well tolerated. Collectively, these results suggest that aliskiren 300 mg may offer treatment benefits compared with irbesartan 300 mg for BP reduction in patients with hypertension and metabolic syndrome.

show abstract

Co-expression of renin-angiotensin system genes in human adipose tissue

Cited by 215 publications

References 34 publications

Knockdown of angiotensinogen by shRNA-mediated RNA interference inhibits human visceral preadipocytes differentiation

Knockdown of angiotensinogen by shRNA-mediated RNA interference inhibits human visceral preadipocytes differentiation

The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

Contact Info

Product

Resources

About